Raghuveer Singh Mali
Bay Institute(US)The Netherlands Cancer Institute(NL)AbbVie (United States)(US)AstraZeneca (United States)(US)
Publications by Year
Research Areas
Mast cells and histamine, Acute Myeloid Leukemia Research, Chronic Lymphocytic Leukemia Research, PI3K/AKT/mTOR signaling in cancer, Chronic Myeloid Leukemia Treatments
Most-Cited Works
- → Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis(2018)376 cited
- → Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models(2020)138 cited
- → Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase(2014)131 cited
- → Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis(2012)116 cited
- → Rho Kinase Regulates the Survival and Transformation of Cells Bearing Oncogenic Forms of KIT, FLT3, and BCR-ABL(2011)97 cited
- → Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis(2014)63 cited